Naproxcinod push deepens NicOx's losses
This article was originally published in Scrip
NicOx's net loss more than doubled in 2008 as the company ramped up its spending in preparation of naproxcinod's commercial launch. The French firm's full-year loss widened to €73.9 million following a significant rise in R&D costs for the osteoarthritis drug.
You may also be interested in...
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.